Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin aspart biosimilar - Biocon/Viatris

Next Previous
X
Search
Drug Profile

Insulin aspart biosimilar - Biocon/Viatris

Alternative Names: Kixelle; MYL-1601D

Latest Information Update: 03 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon
  • Developer Biocon; Viatris Inc
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus
  • Phase III Type 1 diabetes mellitus

Most Recent Events

  • 03 Aug 2023 Launched for Diabetes mellitus in Canada (SC) (Biocon website, August 2023)
  • 29 Nov 2022 Biocon acquires global biosimilars business of its partner Viatris Inc
  • 10 Nov 2021 Health Canada approves insulin aspart biosimilar for treatment of Diabetes mellitus in Canada

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top